Lipid Nanoparticles Market By Type (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, Others), By Application (Therapeutics, Research) By End User (Pharmaceutical and Biotechnology Companies, Acedemic and Research Institutes, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The global lipid nanoparticles market was valued at $0.9 billion in 2023, and is projected to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033
Lipid nanoparticles (LNPs) are nanoscale particles ranging from 10 to 1000 nanometers in diameter, primarily composed of lipids. They are designed to encapsulate therapeutic agents such as drugs, vaccines, and genetic materials, protecting them from degradation and enhancing their delivery and efficacy. LNPs can mimic the structure of biological membranes, making them biocompatible and capable of efficiently interacting with and penetrating cells. Their lipid composition typically includes phospholipids, cholesterol, and other lipid molecules that aid in stabilizing the nanoparticle structure and controlling the release of the encapsulated cargo.
The growth of the lipid nanoparticles market is driven by rise in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and neurological disorders, and surge in demand for advanced drug delivery systems. These conditions often require long-term treatment with drugs that have severe side effects when administered through traditional methods. LNPs offer a promising alternative by enabling targeted and sustained delivery of therapeutic agents, thereby reducing systemic side effects and improving patient compliance. In oncology, for instance, LNPs are used to deliver chemotherapeutic agents directly to tumor cells, minimizing damage to healthy tissues.
However, high cost associated with the production and development of LNP-based formulations, as the manufacturing process involves sophisticated technology and stringent quality control measures to ensure the stability and efficacy of the nanoparticles, leads to increased production costs which limit the market growth. On the contrary, advances in nanotechnology facilitated the development of lipid nanoparticles with enhanced stability, targeted delivery, and controlled release properties. This opened new avenues for drug delivery, allowing for more effective and efficient therapeutic interventions. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA) -based therapeutics announced that they had entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.
Segmentation Overview
The lipid nanoparticles market analysis is segmented into type, application, end user, and region. Depending on type, the market is categorized into solid lipid nanoparticles, nanostructured lipid carriers, and others. By application, it is bifurcated into therapeutics and research. As per end user, the market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By type, the solid lipid nanoparticles segment held the highest market share in 2023.
Depending on the application, the therapeutics segment accounted for maximum share in the market in 2023.
According to end user, the pharmaceutical & biotechnology companies have been the largest shareholder in the market in 2023.
Region wise, North America dominated the lipid nanoparticles market in 2023.
Competitive Scenario
The major players operating in the lipid nanoparticles market include ABP Biosciences, LLC., Merck KGaA, Cytiva, CD Bioparticles, CordenPharma, Precigenome LLC., Beam Therapeutics, Acuitas Therapeutics, GENEVANT SCIENCES CORPORATION, and Helix Biotech, Inc. Other players in lipid nanoparticles market includes Arbutus Biopharma, and Croda International Plc. These players have adopted several strategies, including mergers & acquisitions, collaborations, product innovation & diversification, and partnerships, to maintain their foothold in the market.
Key Market Segments
By Type
Solid Lipid Nanoparticles
Nanostructured Lipid Carriers
Others
By Application
Therapeutics
Research
By End User
Pharmaceutical and Biotechnology Companies
Acedemic and Research Institutes
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ABP Biosciences, LLC.
Merck KGaA
Cytiva
CD Bioparticles
CordenPharma
Precigenome LLC.
Beam Therapeutics
Acuitas Therapeutics.
Helix Biotech, Inc.
Genevant Sciences Corporation
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Solid Lipid Nanoparticles
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Nanostructured Lipid Carriers
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Therapeutics
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Research
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Pharmaceutical And Biotechnology Companies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Acedemic And Research Institutes
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Others
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Lipid Nanoparticles Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Lipid Nanoparticles Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Lipid Nanoparticles Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Lipid Nanoparticles Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Lipid Nanoparticles Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Lipid Nanoparticles Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Lipid Nanoparticles Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Lipid Nanoparticles Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Lipid Nanoparticles Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Lipid Nanoparticles Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Lipid Nanoparticles Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Lipid Nanoparticles Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. Australia Lipid Nanoparticles Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Lipid Nanoparticles Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Lipid Nanoparticles Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Lipid Nanoparticles Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Lipid Nanoparticles Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Lipid Nanoparticles Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. ABP Biosciences, LLC.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Merck KGaA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Cytiva
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. CD Bioparticles
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. CordenPharma
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Precigenome LLC.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Beam Therapeutics
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Acuitas Therapeutics.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Helix Biotech, Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Genevant Sciences Corporation
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL LIPID NANOPARTICLES MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. LIPID NANOPARTICLES MARKET FOR SOLID LIPID NANOPARTICLES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. LIPID NANOPARTICLES MARKET FOR NANOSTRUCTURED LIPID CARRIERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. LIPID NANOPARTICLES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL LIPID NANOPARTICLES MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 6. LIPID NANOPARTICLES MARKET FOR THERAPEUTICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. LIPID NANOPARTICLES MARKET FOR RESEARCH, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL LIPID NANOPARTICLES MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 9. LIPID NANOPARTICLES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. LIPID NANOPARTICLES MARKET FOR ACEDEMIC AND RESEARCH INSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. LIPID NANOPARTICLES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. LIPID NANOPARTICLES MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. NORTH AMERICA LIPID NANOPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 16. NORTH AMERICA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 17. U.S. LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 19. U.S. LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 20. CANADA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 22. CANADA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 23. MEXICO LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 25. MEXICO LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 26. EUROPE LIPID NANOPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 29. EUROPE LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 30. GERMANY LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 31. GERMANY LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 32. GERMANY LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 33. FRANCE LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 35. FRANCE LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 36. UK LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 37. UK LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 38. UK LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 39. ITALY LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 41. ITALY LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 42. SPAIN LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 44. SPAIN LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 45. REST OF EUROPE LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 47. REST OF EUROPE LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 48. ASIA-PACIFIC LIPID NANOPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 51. ASIA-PACIFIC LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 52. JAPAN LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 53. JAPAN LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 54. JAPAN LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 55. CHINA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 57. CHINA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 58. INDIA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 59. INDIA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 60. INDIA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 61. AUSTRALIA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 62. AUSTRALIA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 63. AUSTRALIA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 64. SOUTH KOREA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 66. SOUTH KOREA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 67. REST OF ASIA-PACIFIC LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 69. REST OF ASIA-PACIFIC LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 70. LAMEA LIPID NANOPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 73. LAMEA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 74. BRAZIL LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 76. BRAZIL LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 77. SAUDI ARABIA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 78. SAUDI ARABIA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 79. SAUDI ARABIA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 80. SOUTH AFRICA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 82. SOUTH AFRICA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 83. REST OF LAMEA LIPID NANOPARTICLES, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA LIPID NANOPARTICLES, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 85. REST OF LAMEA LIPID NANOPARTICLES, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 86. ABP BIOSCIENCES, LLC.: KEY EXECUTIVES
- TABLE 87. ABP BIOSCIENCES, LLC.: COMPANY SNAPSHOT
- TABLE 88. ABP BIOSCIENCES, LLC.: OPERATING SEGMENTS
- TABLE 89. ABP BIOSCIENCES, LLC.: PRODUCT PORTFOLIO
- TABLE 90. ABP BIOSCIENCES, LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 91. MERCK KGAA: KEY EXECUTIVES
- TABLE 92. MERCK KGAA: COMPANY SNAPSHOT
- TABLE 93. MERCK KGAA: OPERATING SEGMENTS
- TABLE 94. MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 95. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96. CYTIVA: KEY EXECUTIVES
- TABLE 97. CYTIVA: COMPANY SNAPSHOT
- TABLE 98. CYTIVA: OPERATING SEGMENTS
- TABLE 99. CYTIVA: PRODUCT PORTFOLIO
- TABLE 100. CYTIVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101. CD BIOPARTICLES: KEY EXECUTIVES
- TABLE 102. CD BIOPARTICLES: COMPANY SNAPSHOT
- TABLE 103. CD BIOPARTICLES: OPERATING SEGMENTS
- TABLE 104. CD BIOPARTICLES: PRODUCT PORTFOLIO
- TABLE 105. CD BIOPARTICLES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106. CORDENPHARMA: KEY EXECUTIVES
- TABLE 107. CORDENPHARMA: COMPANY SNAPSHOT
- TABLE 108. CORDENPHARMA: OPERATING SEGMENTS
- TABLE 109. CORDENPHARMA: PRODUCT PORTFOLIO
- TABLE 110. CORDENPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111. PRECIGENOME LLC.: KEY EXECUTIVES
- TABLE 112. PRECIGENOME LLC.: COMPANY SNAPSHOT
- TABLE 113. PRECIGENOME LLC.: OPERATING SEGMENTS
- TABLE 114. PRECIGENOME LLC.: PRODUCT PORTFOLIO
- TABLE 115. PRECIGENOME LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116. BEAM THERAPEUTICS: KEY EXECUTIVES
- TABLE 117. BEAM THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 118. BEAM THERAPEUTICS: OPERATING SEGMENTS
- TABLE 119. BEAM THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 120. BEAM THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121. ACUITAS THERAPEUTICS.: KEY EXECUTIVES
- TABLE 122. ACUITAS THERAPEUTICS.: COMPANY SNAPSHOT
- TABLE 123. ACUITAS THERAPEUTICS.: OPERATING SEGMENTS
- TABLE 124. ACUITAS THERAPEUTICS.: PRODUCT PORTFOLIO
- TABLE 125. ACUITAS THERAPEUTICS.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126. HELIX BIOTECH, INC.: KEY EXECUTIVES
- TABLE 127. HELIX BIOTECH, INC.: COMPANY SNAPSHOT
- TABLE 128. HELIX BIOTECH, INC.: OPERATING SEGMENTS
- TABLE 129. HELIX BIOTECH, INC.: PRODUCT PORTFOLIO
- TABLE 130. HELIX BIOTECH, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131. GENEVANT SCIENCES CORPORATION: KEY EXECUTIVES
- TABLE 132. GENEVANT SCIENCES CORPORATION: COMPANY SNAPSHOT
- TABLE 133. GENEVANT SCIENCES CORPORATION: OPERATING SEGMENTS
- TABLE 134. GENEVANT SCIENCES CORPORATION: PRODUCT PORTFOLIO
- TABLE 135. GENEVANT SCIENCES CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL LIPID NANOPARTICLES MARKET SEGMENTATION
- FIGURE 2. GLOBAL LIPID NANOPARTICLES MARKET
- FIGURE 3. SEGMENTATION LIPID NANOPARTICLES MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN LIPID NANOPARTICLES MARKET
- FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 8. LOW THREAT OF SUBSTITUTION
- FIGURE 9. HIGH COMPETITIVE RIVALRY
- FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLIPID NANOPARTICLES MARKET
- FIGURE 11. GLOBAL LIPID NANOPARTICLES MARKET SEGMENTATION, BY TYPE
- FIGURE 12. LIPID NANOPARTICLES MARKET FOR SOLID LIPID NANOPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. LIPID NANOPARTICLES MARKET FOR NANOSTRUCTURED LIPID CARRIERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. LIPID NANOPARTICLES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. GLOBAL LIPID NANOPARTICLES MARKET SEGMENTATION, BY APPLICATION
- FIGURE 16. LIPID NANOPARTICLES MARKET FOR THERAPEUTICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. LIPID NANOPARTICLES MARKET FOR RESEARCH, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. GLOBAL LIPID NANOPARTICLES MARKET SEGMENTATION, BY END USER
- FIGURE 19. LIPID NANOPARTICLES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. LIPID NANOPARTICLES MARKET FOR ACEDEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. LIPID NANOPARTICLES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 26. COMPETITIVE DASHBOARD
- FIGURE 27. COMPETITIVE HEATMAP: LIPID NANOPARTICLES MARKET
- FIGURE 28. TOP PLAYER POSITIONING, 2023
- FIGURE 29. ABP BIOSCIENCES, LLC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 30. ABP BIOSCIENCES, LLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 31. ABP BIOSCIENCES, LLC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 32. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 33. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 34. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 35. CYTIVA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 36. CYTIVA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. CYTIVA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. CD BIOPARTICLES: NET SALES, 2021-2023 ($BILLION)
- FIGURE 39. CD BIOPARTICLES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. CD BIOPARTICLES: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. CORDENPHARMA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 42. CORDENPHARMA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. CORDENPHARMA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. PRECIGENOME LLC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 45. PRECIGENOME LLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. PRECIGENOME LLC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. BEAM THERAPEUTICS: NET SALES, 2021-2023 ($BILLION)
- FIGURE 48. BEAM THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. BEAM THERAPEUTICS: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. ACUITAS THERAPEUTICS.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 51. ACUITAS THERAPEUTICS.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. ACUITAS THERAPEUTICS.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. HELIX BIOTECH, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 54. HELIX BIOTECH, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. HELIX BIOTECH, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. GENEVANT SCIENCES CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 57. GENEVANT SCIENCES CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. GENEVANT SCIENCES CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook